Great link tcooper21.
It's hard to believe how much impact the Macquarie scare-mongering has had on the share price of this stock at the very moment such impressive sales data were released.
Makes me wonder... Has Macquarie been shorting this stock?
As well as checking out tcoooper21's link, checkout this article published in the Journal of the American Heart Association, 15 November 2013:
http://jaha.ahajournals.org/content/2/6/e000272.full
The conclusion states:
"Given the very large population of patients in the United States who suffer from hypogonadism coupled with a projection of ˜481 000 new cases of hypogonadism annually, an extensive amount of attention has been dedicated to the interplay between testosterone and various aspects of cardiovascular health and well-being. Low endogenous bioavailable testosterone levels have been shown to be associated with higher rates of all-cause and cardiovascular-related mortality. Patients suffering from CAD (Coronary Artery Disease), CHF (Congestive Heart Failure), T2DM (Type 2 Diabetes Mellitus), and obesity have all been shown to have lower levels of endogenous testosterone compared with those in healthy controls. In addition, the severity of CAD and CHF correlates with the degree of testosterone deficiency."
So...
The crux...
Testosterone deficiency is associated with increased rates of heart disease.
Therefore...
Properly managed testosterone replacement therapy should be associated with decreased rates of heart disease.
It is important to note that this article represents "a comprehensive review of the clinical literature that has examined the associations between testosterone and cardiovascular disease".
Its wide-ranging analysis is therefore in stark contrast to the two isolated studies that have created such a fuss in relation to this company and its shareprice over the past few days.
Hopefully the fear and panic will soon subside and the performance of this company will return to center stage.
Add to My Watchlist
What is My Watchlist?
